Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 <br/><b>Interventions</b>: Drug: Secutrelvir; Drug: Placebo <br/><b>Sponsors</b>: Shionogi <br/><b>Not yet recruiting</b>

  2. Kinesiotaping Versus Physiotherapy for Post-Covid-19 Back Pain

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Post-COVID-19 Syndrome; Back Pain; Musculoskeletal Pain <br/><b>Interventions</b>: Device: Kinesiotaping; Procedure: Conventional Physiotherapy <br/><b>Sponsors</b>: Medipol University <br/><b>Completed</b>

  3. Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID Fatigue; Post COVID Dysautonomia <br/><b>Interventions</b>: Other: Ketogenic Metabolic Therapy; Behavioral: Lifestyle Intervention <br/><b>Sponsors</b>: National University of Natural Medicine <br/><b>Completed</b>

  4. Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: SARS CoV 2 Infection; Influenza A Virus Infection; Influenza B Virus Infection <br/><b>Interventions</b>: Diagnostic Test: Diagnostic test for SARS-CoV-2, influenza A and influenza B <br/><b>Sponsors</b>: Biocrucible Ltd <br/><b>Not yet recruiting</b>

  5. Effect of Surgical Masks in Preventing Acute Respiratory Infections

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Acute Respiratory Infections (ARIs); Influenza; COVID - 19 <br/><b>Interventions</b>: Behavioral: Surgical masks <br/><b>Sponsors</b>: Chiba University <br/><b>Enrolling by invitation</b>

  6. A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

    Tue, 28 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Vaccines <br/><b>Interventions</b>: Biological: BNT162b2 Vaccine; Biological: Tdap Vaccine <br/><b>Sponsors</b>: BioNTech SE; Pfizer <br/><b>Not yet recruiting</b>

  7. A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

    Mon, 27 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID - 19 <br/><b>Interventions</b>: Biological: GC4006A; Drug: Normal Saline <br/><b>Sponsors</b>: GC Biopharma Corp <br/><b>Active, not recruiting</b>

  8. COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival

    Mon, 27 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Cancer; Immune Checkpoint Inhibitors; COVID-19 Vaccination; Survival <br/><b>Sponsors</b>: Groupe Hospitalier Pitie-Salpetriere; APHP; Sorbonne University; Institut National de la Santé Et de la Recherche Médicale, France <br/><b>Active, not recruiting</b>

  9. Micro-choice-based Intervention for Multicausal Fatigue

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Multicausal Fatigue; Fatigue; Post COVID Condition; Long COVID Syndrome; Postviral Fatigue <br/><b>Interventions</b>: Behavioral: Micro-choice-based intervention <br/><b>Sponsors</b>: University Hospital, Basel, Switzerland; Kämpf- Bötschi Stiftung; propatient Forschungsstiftung <br/><b>Recruiting</b>

  10. CD19-B Cell Depletion in PAIS-ME/CFS Patients

    Fri, 24 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Post-acute Infectious Syndrome (PAIS); Post-COVID 19 Condition (PCC or Long COVID); Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) <br/><b>Interventions</b>: Drug: Inebilizumab; Drug: Placebo <br/><b>Sponsors</b>: Charite University, Berlin, Germany <br/><b>Not yet recruiting</b>

  11. Different Treatment Options Used for Post Covid-19 Syndrome

    Tue, 28 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Post COVID-19 Syndrome; Ginkgo Biloba; Piracetam <br/><b>Interventions</b>: Drug: Ginkgo biloba; Drug: Piracetam; Drug: Ginkgo biloba and Piracetam <br/><b>Sponsors</b>: Beni-Suef University <br/><b>Completed</b>

  12. Treatment and Outcomes in Patients With COVID-19 and Competing Acute Surgical Diseases in Moscow

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Emergency Surgery; Abdominal Surgery; Real-World Data <br/><b>Interventions</b>: Procedure: Surgical and Interventional Management of Acute Surgical Conditions <br/><b>Sponsors</b>: Pirogov Russian National Research Medical University; Moscow Multidisciplinary Clinical Center "Kommunarka" <br/><b>Completed</b>

  13. Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-CoV-2 <br/><b>Interventions</b>: Drug: Molnupiravir <br/><b>Sponsors</b>: Charles University, Czech Republic; Institute of Health Information and Statistics of the Czech Republic <br/><b>Completed</b>

  14. Microbiome-Based Risk Prediction of SARS-CoV-2 in Children and Families (PREDICOL)

    Tue, 21 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Heathly Subjects Susceptible to SARS-CoV-2 Infection <br/><b>Sponsors</b>: Spanish National Research Council; Interdisciplinary Thematic Platform (PTI+) Global Health (CSIC) <br/><b>Completed</b>

  15. Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID

    Wed, 29 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Long Covid; Depression; Anxiety <br/><b>Interventions</b>: Device: Rauha® Digital Therapeutic Platform (Toivoa-004) <br/><b>Sponsors</b>: Toivoa Inc; National Institute of Nursing Research (NINR) <br/><b>Withdrawn</b>

  16. The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms

    Tue, 21 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID - 19; Depression - Major Depressive Disorder <br/><b>Interventions</b>: Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid); Dietary Supplement: Specialized Pro-Resolving Lipid Mediator; Dietary Supplement: Placebo <br/><b>Sponsors</b>: National Science and Technology Council, Taiwan <br/><b>Completed</b>

  17. Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients

    Tue, 21 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; COVID-19 (SARS-CoV-2 Infection) <br/><b>Interventions</b>: Biological: LB-DTK-COV19 <br/><b>Sponsors</b>: LucasBio <br/><b>Active, not recruiting</b>

  18. Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Post-COVID Conditions; Fatigue; Cognitive Dysfunction <br/><b>Interventions</b>: Device: Transcranial Direct Current Stimulation <br/><b>Sponsors</b>: University of Las Palmas de Gran Canaria; Fundación Canaria Instituto de Investigación Sanitaria de Canarias; Canary Islands Health Service <br/><b>Not yet recruiting</b>

  19. A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID -19 <br/><b>Interventions</b>: Biological: RVX-sCPD9 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Not yet recruiting</b>

  20. Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infections (RTI); Influenza -Like Illness; Influenza; COVID - 19; RSV Infections; Rhinovirus Infection; Metapneumovirus Infection <br/><b>Interventions</b>: Diagnostic Test: saliva sampling; Diagnostic Test: Nasopharyngeal swab <br/><b>Sponsors</b>: Institut National de la Santé Et de la Recherche Médicale, France <br/><b>Recruiting</b>

  21. A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

    Tue, 28 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus Disease 2019; Coronavirus Disease 2019 (COVID-19); COVID-19 (Coronavirus Disease 2019); Upper Respiratory Tract Infections; Respiratory Tract Infection; Respiratory Tract Diseases; COVID-19; COVID-19 Infection; COVID-19 SARS-CoV-2 Infection; Pneumonia; Lung Diseases <br/><b>Interventions</b>: Drug: Ibuzatrelvir co-process API film coated tablet; Drug: Ibuzatrelvir filmcoated tablet <br/><b>Sponsors</b>: Pfizer <br/><b>Completed</b>

  22. A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: OCU500 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  23. Nasal Swab Objective and Statistical Evaluation (NOSE Study)

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: SARS Coronavirus 2 RT-PCR Testing <br/><b>Sponsors</b>: VA Office of Research and Development <br/><b>Completed</b>

  24. Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID - 19; SARS CoV-2 <br/><b>Interventions</b>: Biological: COVID-19 Vaccines; Biological: COVID-19 Vaccines <br/><b>Sponsors</b>: Rokote Laboratories Finland Oy; Oy Medfiles Ltd; Estimates OY <br/><b>Active, not recruiting</b>

  25. Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Drug: Keytruda <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Not yet recruiting</b>

  26. Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: NDV-HXP-S-KP.2; Biological: COVID-19 mRNA Vaccine <br/><b>Sponsors</b>: CastleVax Inc. <br/><b>Active, not recruiting</b>

  27. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia <br/><b>Sponsors</b>: National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Enrolling by invitation</b>

  28. Centralization and Oncologic Outcomes in Ovarian Cancer

    Fri, 24 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Epithelial Ovarian Cancer; Ovarian Neoplasms; Advanced Ovarian Cancer <br/><b>Interventions</b>: Other: No Intervention: Observational Cohort <br/><b>Sponsors</b>: Azienda USL Reggio Emilia - IRCCS; AUSL di Modena - Ospedale Ramazzini di Carpi; AUSL di Modena - Ospedale di Mirandola; AUSL di Modena - Ospedale Civile di Sassuolo; AUSL di Modena - Ospedale di Pavullo nel Frignano; AUSL di Modena - Ospedale di Vignola; Azienda Ospedaliero-Universitaria di Modena <br/><b>Recruiting</b>

  29. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Thu, 30 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  30. Attention, Memory and Quality of Life in Post-COVID-19 Adults

    Fri, 24 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome; Long COVID; Brain Fog <br/><b>Interventions</b>: Behavioral: qEEG-neurofeedback; Behavioral: SHAM qEEG-neurofeedback <br/><b>Sponsors</b>: Jade Carvalho Da Silva; Santos Dumont Institute <br/><b>Completed</b>

  31. Evaluation of the Gambling Habits of Adolescents and Young Adults Post-COVID-19 and Implementation of a Digital Escape Room Intervention for Preventing Gambling in High School Students

    Thu, 23 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Mental Health <br/><b>Interventions</b>: Behavioral: GAMBL-OUT program <br/><b>Sponsors</b>: Hospital Miguel Servet <br/><b>Recruiting</b>

  32. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 SARS-CoV-2 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: placebo <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  33. tVNS in Long COVID-19

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Chronic Fatigue Syndrome <br/><b>Interventions</b>: Device: Transcutaneous vagus nerve stimulator <br/><b>Sponsors</b>: Icahn School of Medicine at Mount Sinai <br/><b>Active, not recruiting</b>

  34. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: PASC Post Acute Sequelae of COVID-19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  35. RECOVER-AUTONOMIC Platform Protocol

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Long Covid19; Long Covid-19 <br/><b>Interventions</b>: Drug: IVIG + Coordinated Care; Drug: IVIG Placebo + Coordinated Care; Drug: Ivabradine + Coordinated Care; Drug: Ivabradine Placebo + Coordinated Care; Drug: IVIG + Usual Care; Drug: IVIG Placebo + Usual Care; Drug: Ivabradine + Usual Care; Drug: Ivabradine Placebo + Usual Care <br/><b>Sponsors</b>: Kanecia Obie Zimmerman <br/><b>Completed</b>

  36. RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Long Coronavirus Disease 2019 (Covid19); Long Covid-19 <br/><b>Interventions</b>: Drug: IVIG (intravenous immunoglobulin); Drug: IVIG Placebo; Behavioral: Coordinated Care; Behavioral: Usual Care <br/><b>Sponsors</b>: Kanecia Obie Zimmerman <br/><b>Completed</b>

  37. RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

    Thu, 30 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Chinese Herb; Diagnostic Test: Placebo <br/><b>Sponsors</b>: Chinese University of Hong Kong <br/><b>Recruiting</b>

  38. Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

    Wed, 29 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Post COVID-19 Condition (PCC) <br/><b>Interventions</b>: Other: Digital intervention (DiLCoS); Other: Data collection <br/><b>Sponsors</b>: University Hospital, Basel, Switzerland; State Secretariat for Education Research and Innovation, Switzerland; Horizon Europe <br/><b>Completed</b>

  39. Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

    Tue, 21 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Viral Lung Infection and Acute Respiratory Failure <br/><b>Interventions</b>: Drug: Tozorakimab; Drug: Placebo <br/><b>Sponsors</b>: AstraZeneca <br/><b>Recruiting</b>

  40. Effects of Immulina TM Supplements With PASC Patients

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Post Acute COVID-19 Syndrome <br/><b>Interventions</b>: Drug: Immulina TM; Dietary Supplement: Placebo <br/><b>Sponsors</b>: University of Mississippi Medical Center; National Institute of General Medical Sciences (NIGMS) <br/><b>Completed</b>

  41. COVID-19 Vaccine Uptake Trial

    Tue, 21 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Vaccination Refusal; COVID-19 <br/><b>Interventions</b>: Other: Short Message Service (SMS) + Website Link Strategy; Other: Phone Call with Peer Strategy <br/><b>Sponsors</b>: Washington University School of Medicine <br/><b>Completed</b>

  42. Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Hyposmia; COVID-19; Parosmia; Anosmia; SARS-CoV-2 Infection <br/><b>Interventions</b>: Other: Smell training <br/><b>Sponsors</b>: Université du Québec à Trois-Rivières <br/><b>Recruiting</b>

  43. Reducing COVID-19 Related Disability in Rural Community-Dwelling Older Adults Using Smart Technology

    Fri, 24 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Quality of Life; Disabilities Multiple <br/><b>Interventions</b>: Behavioral: Standard Health Education; Behavioral: Self Management <br/><b>Sponsors</b>: University of Missouri-Columbia; National Institute on Aging (NIA) <br/><b>Completed</b>

  44. Long-term COVID and Rehabilitation

    Thu, 30 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Long-COVID <br/><b>Interventions</b>: Dietary Supplement: Mitoquinone; Dietary Supplement: Placebo <br/><b>Sponsors</b>: VA Office of Research and Development <br/><b>Recruiting</b>

  45. COVID-19 Experiences in the SELF Cohort

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Environmental Health Sciences (NIEHS) <br/><b>Enrolling by invitation</b>

  46. Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Systemic Inflammation; Neuroinflammation; Microvascular Thrombosis <br/><b>Interventions</b>: Drug: IV normal saline; Drug: IV immunoglobulin <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Enrolling by invitation</b>

  47. Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

    Thu, 30 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Vaccination; Healthy Volunteer <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  48. Impact of COVID-19 Vaccines on Cerebrovascular Health

    Thu, 30 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Stroke; Stroke, Acute; Stroke, Ischemic; Dementia; Brain Ischemia; Alzheimer Disease; Brain Diseases; Major Adverse Cardiovascular Event; Arterial Thromboembolism; Venous Thromboembolism <br/><b>Interventions</b>: Diagnostic Test: Laboratory tests and Montreal Cognitive Assessment; Diagnostic Test: Laboratory tests and Montreal Cognitive Assessment <br/><b>Sponsors</b>: Chinese University of Hong Kong <br/><b>Completed</b>

  49. A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Parenting; Covid19 <br/><b>Interventions</b>: Behavioral: CARE Program and Valera Application with care manager functionality; Behavioral: Valera Application with care manager functionality; Behavioral: CARE Program; Behavioral: Valera Application; Behavioral: CARE Program and Valera Application <br/><b>Sponsors</b>: Albert Einstein College of Medicine; National Institute of Mental Health (NIMH); University of Miami <br/><b>Active, not recruiting</b>

  50. COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana

    Tue, 21 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19; Vaccine Refusal; Vaccine Hesitancy <br/><b>Interventions</b>: Behavioral: COVID-19 Vaccine Education at the Point of COVID-19 Testing <br/><b>Sponsors</b>: Xavier University of Louisiana.; National Institute on Minority Health and Health Disparities (NIMHD) <br/><b>Completed</b>

  51. Chinese Medicine for Patients With LCOVID-19 Symptoms

    Mon, 27 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Drug: COVID Rehab Formula granules; Other: Placebo granules <br/><b>Sponsors</b>: Chinese University of Hong Kong <br/><b>Completed</b>

  52. Leveraging Social Networks to Increase COVID-19 Testing Uptake

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Covid-19; Substance Use; Opioid Use <br/><b>Interventions</b>: Behavioral: Chain-referral; Behavioral: Credible Messenger <br/><b>Sponsors</b>: New York State Psychiatric Institute; Alliance for Postive Change; Argus Community Inc.; Columbia University; National Institute on Drug Abuse (NIDA) <br/><b>Completed</b>

  53. Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 Infection <br/><b>Interventions</b>: Dietary Supplement: Vitamin D3 <br/><b>Sponsors</b>: University of Chicago; Rush University Medical Center <br/><b>Completed</b>

  54. Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

    Thu, 30 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Influenza; COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Completed</b>

  55. Couple HOPES and COVID-19

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Posttraumatic Stress Disorder <br/><b>Interventions</b>: Behavioral: Couple HOPES Guided, Internet-Delivered, Self-Help Intervention <br/><b>Sponsors</b>: York University <br/><b>Completed</b>

  56. Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19

    Fri, 31 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: Solid Carcinoma; Post Traumatic Stress Disorder; Covid19 <br/><b>Interventions</b>: Other: Psychological support <br/><b>Sponsors</b>: Centre Francois Baclesse <br/><b>Completed</b>

  57. Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Coronavirus Disease 19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  58. Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce

    Wed, 22 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Other: Questionnaire Administration <br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI) <br/><b>Recruiting</b>

  59. Presence of SARS-CoV-2 (COVID-19) in Semen: Impact on Fertility Preservation in Male Oncological Patients ?

    Mon, 03 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Sperm Preservation in Oncological Patients; Fertility; Cryopreservation <br/><b>Interventions</b>: Diagnostic Test: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics <br/><b>Sponsors</b>: University Hospital, Clermont-Ferrand; Agence de La Biomédecine <br/><b>Completed</b>

  60. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  61. Genetics of COVID-19 Susceptibility and Manifestations

    Mon, 27 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Coronavirus 2019 <br/><b>Sponsors</b>: National Human Genome Research Institute (NHGRI) <br/><b>Completed</b>

  62. Long-term Impact of Infection With Novel Coronavirus (COVID-19)

    Thu, 23 Jul 2026 04:00:00 -0000

    <b>Conditions</b>: COVID <br/><b>Sponsors</b>: University of California, San Francisco <br/><b>Recruiting</b>

  63. Viral Infections in Healthy and Immunocompromised Hosts

    Tue, 04 Aug 2026 04:00:00 -0000

    <b>Conditions</b>: Anogenital Herpes; COVID-19; Herpes Labialis <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>